Coya Therapeutics (COYA) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from the proposed public offering for working capital and other general corporate purposes, including funding its clinical development plan. Lucid Capital Markets is acting as sole book-running manager for the proposed public offering.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Positive Outlook for Coya Therapeutics Driven by Promising COYA-302 Clinical Developments and Regulatory Support
- Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study
- Promising Outlook for COYA 302 Amidst Phase 2 Trial and Near-Term Catalysts Justifies Buy Rating
- Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302
- Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study